• Tennor Therapeutics shareholders approved the 2026 H Share Award Scheme at an extraordinary general meeting on October 23, 2026.
• The proposal received 28,990,948 votes in favor, representing 95.41% of votes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tennor Therapeutics (Suzhou) Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261023-12381899), on October 23, 2026, and is solely responsible for the information contained therein.